tert-butyl (2S)-4-methyl-2-[5-[4-[2-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-4,5-dihydro-3H-benzo[e]benzimidazol-7-yl]ethynyl]phenyl]-1H-imidazol-2-yl]-2,5-dihydropyrrole-1-carboxylate | 1352393-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl (2S)-4-methyl-2-[5-[4-[2-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-4,5-dihydro-3H-benzo[e]benzimidazol-7-yl]ethynyl]phenyl]-1H-imidazol-2-yl]-2,5-dihydropyrrole-1-carboxylate
• CAS: 1352393-52-2
• 化学式: C₄₁H₄₆N₆O₄
• 分子量: 686.854
• InChiKey: BGXMKGDFKMUSRL-HEVIKAOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  51
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] INHIBITORS OF HCV NS5A PROTEIN<br/>[FR] INHIBITEURS DE LA PROTÉINE NS5A DU VHC
  申请人：PRESIDIO PHARMACEUTICALS INC

  公开号：WO2011156543A2

  公开（公告）日：2011-12-15

  Antiviral compounds may be used to inhibit or reduce the activity of Hepatitis C virus (HCV), particularly HCV's NS5A protein. In these contexts, inhibition and reduction of activity of the NS5A protein refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound. The inhibition or reduction in the measured activity is at least a 10% reduction or inhibition. The compounds and their isomeric forms and pharmaceutically acceptable salts thereof are useful in treating and preventing HCV infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the HCV lifecycle.